lutetium-lu-177-dotatate and Thymus-Neoplasms

lutetium-lu-177-dotatate has been researched along with Thymus-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for lutetium-lu-177-dotatate and Thymus-Neoplasms

ArticleYear
Prolonged response to
    Investigational new drugs, 2020, Volume: 38, Issue:4

    Thymic neuro endocrine tumor (tNET) are extremely rare malignancies with poor prognosis, requiring investigation of novel therapeutic approaches.

    Topics: Adult; Bone Marrow Neoplasms; Humans; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, Peptide; Thymus Neoplasms; Treatment Outcome

2020
Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy.
    Clinical nuclear medicine, 2015, Volume: 40, Issue:12

    Neuroendocrine tumors have a propensity to metastasize to the heart, although the reason for this remains unknown. A review of 251 neuroendocrine tumor patients treated with Lu DOTATATE peptide receptor radionuclide therapy or I-MIBG therapy at our institution since 2003 revealed 2 patients with cardiac metastases (incidence, 0.8%), one treated with Lu DOTATATE and one with I-MIBG. We present the imaging findings of these 2 patients, as well as their management and responses to therapy.

    Topics: 3-Iodobenzylguanidine; Aged; Female; Heart Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiopharmaceuticals; Thymus Neoplasms

2015